Compare TARS & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARS | WRBY |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2020 | 2021 |
| Metric | TARS | WRBY |
|---|---|---|
| Price | $65.71 | $25.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $89.00 | $27.10 |
| AVG Volume (30 Days) | 408.4K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 105.88 |
| EPS | N/A | ★ 0.01 |
| Revenue | $451,360,000.00 | ★ $871,905,000.00 |
| Revenue This Year | $56.56 | $14.48 |
| Revenue Next Year | $29.94 | $16.41 |
| P/E Ratio | ★ N/A | $2,561.50 |
| Revenue Growth | ★ 146.71 | 13.04 |
| 52 Week Low | $38.51 | $14.72 |
| 52 Week High | $85.25 | $31.00 |
| Indicator | TARS | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 63.17 |
| Support Level | $65.62 | $25.23 |
| Resistance Level | $67.70 | $28.19 |
| Average True Range (ATR) | 3.04 | 1.32 |
| MACD | -0.37 | 0.57 |
| Stochastic Oscillator | 12.62 | 91.86 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.